138 related articles for article (PubMed ID: 10474692)
1. The role of morphine glucuronides in cancer pain.
Mercadante S
Palliat Med; 1999 Mar; 13(2):95-104. PubMed ID: 10474692
[TBL] [Abstract][Full Text] [Related]
2. Persistent pain associated with long-term intrathecal morphine administration.
Parris WC; Janicki PK; Johnson B; Livengood J; Mathews L
South Med J; 1996 Apr; 89(4):417-9. PubMed ID: 8614885
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.
Andersen G; Sjøgren P; Hansen SH; Jensen NH; Christrup L
Eur J Pain; 2004 Jun; 8(3):263-71. PubMed ID: 15109977
[TBL] [Abstract][Full Text] [Related]
5. A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain.
Hoffman M; Xu JC; Smith C; Fanelli C; Pascal V; Degaetano C; Meenan G; Lehrer M; Lesser M; Citron M
Cancer Invest; 1997; 15(6):542-7. PubMed ID: 9412659
[TBL] [Abstract][Full Text] [Related]
6. A novel metabolic pathway of morphine: formation of morphine glucosides in cancer patients.
Chen XY; Zhao LM; Zhong DF
Br J Clin Pharmacol; 2003 Jun; 55(6):570-8. PubMed ID: 12814451
[TBL] [Abstract][Full Text] [Related]
7. Relationship between plasma concentrations of morphine and its metabolites and pain in cancer patients.
Sakurada T; Takada S; Eguchi H; Izumi K; Satoh N; Ueda S
Pharm World Sci; 2010 Dec; 32(6):737-43. PubMed ID: 20730493
[TBL] [Abstract][Full Text] [Related]
8. Morphine-6-glucuronide, an active morphine metabolite for the potential treatment of post-operative pain.
Joshi GP
Curr Opin Investig Drugs; 2008 Jul; 9(7):786-99. PubMed ID: 18600584
[TBL] [Abstract][Full Text] [Related]
9. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans.
Aasmundstad TA; Størset P
Hum Exp Toxicol; 1998 Jun; 17(6):347-52. PubMed ID: 9688360
[TBL] [Abstract][Full Text] [Related]
10. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.
Klepstad P; Rakvåg TT; Kaasa S; Holthe M; Dale O; Borchgrevink PC; Baar C; Vikan T; Krokan HE; Skorpen F
Acta Anaesthesiol Scand; 2004 Nov; 48(10):1232-9. PubMed ID: 15504181
[TBL] [Abstract][Full Text] [Related]
11. [Analgesic effect of morphine and its metabolites administered by an intracerebroventricular route].
Serrié A
Bull Acad Natl Med; 1995 Jun; 179(6):1237-52; discussion 1252-3. PubMed ID: 8542351
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries.
Perreault S; Choinière M; du Souich PB; Bellavance F; Beauregard G
Ann Pharmacother; 2001 Dec; 35(12):1588-92. PubMed ID: 11793627
[TBL] [Abstract][Full Text] [Related]
13. Plasma morphine and metabolite concentrations are associated with clinical effects of morphine in cancer patients.
Gretton SK; Ross JR; Rutter D; Sato H; Droney JM; Welsh KI; Joel S; Riley J
J Pain Symptom Manage; 2013 Apr; 45(4):670-80. PubMed ID: 22995672
[TBL] [Abstract][Full Text] [Related]
14. [Morphinic analgesics. Principles and rules of use].
Soubrie C
Rev Prat; 1993 Apr; 43(8):1049-51. PubMed ID: 8102007
[No Abstract] [Full Text] [Related]
15. Morphine glucuronidation increases its analgesic effect in guinea pigs.
Oliveira A; Pinho D; Albino-Teixeira A; Medeiros R; Dinis-Oliveira RJ; Carvalho F
Life Sci; 2014 Jul; 109(2):104-10. PubMed ID: 24968302
[TBL] [Abstract][Full Text] [Related]
16. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain.
Yamada H; Ishii K; Ishii Y; Ieiri I; Nishio S; Morioka T; Oguri K
J Toxicol Sci; 2003 Dec; 28(5):395-401. PubMed ID: 14746343
[TBL] [Abstract][Full Text] [Related]
17. Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor.
Frölich N; Dees C; Paetz C; Ren X; Lohse MJ; Nikolaev VO; Zenk MH
Biochem Pharmacol; 2011 May; 81(10):1248-54. PubMed ID: 21396918
[TBL] [Abstract][Full Text] [Related]
18. Pain: morphine, metabolites, mambas, and mutations.
Woolf CJ
Lancet Neurol; 2013 Jan; 12(1):18-20. PubMed ID: 23237896
[No Abstract] [Full Text] [Related]
19. Do we have clarity on the therapeutic levels of morphine and its metabolites: seeking answers for the dilemma?
Srinivas NR
J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):163-6. PubMed ID: 23789848
[TBL] [Abstract][Full Text] [Related]
20. 1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology.
Mather LE
Reg Anesth; 1995; 20(4):263-82. PubMed ID: 7577774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
